LABORATOIRES THEA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
59
Trial Phases
5 Phases
Drug Approvals
45
Drug Approvals
MONOPROST 50 MICROGRAMOS/ML COLIRIO EN SOLUCION EN ENVASE UNIDOSIS
- Approval Date
- Jul 14, 2025
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (56 trials with phase data)• Click on a phase to view related trials
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
- Conditions
- Moderate to Severe Vernal Keratoconjunctivitis
- Interventions
- Diagnostic Test: Slit Lamp ExaminationDiagnostic Test: Far Best Corrected Visual Acuity (BCVA)Drug: T1695Diagnostic Test: Corneal fluorescein staining score on modified Oxford scale
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 120
- Registration Number
- NCT07169695
Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease
- Conditions
- Dry Eye Disease (DED)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 30
- Registration Number
- NCT07007702
- Locations
- 🇦🇹
Universitätsklinik für Klinische Pharmakologie, Allgemeines Krankenhaus Wien, Wien, Austria
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
- Conditions
- Dry Eye Disease (DED)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 30
- Registration Number
- NCT06903741
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
- Conditions
- Leber Congenital Amaurosis 10Sensation DisordersEye DiseasesBlindnessEye Disorders CongenitalLeber Congenital AmaurosisNeurological ManifestationsEye Diseases, HereditaryVision DisorderRetinal Disease
- Interventions
- Other: Placebo IVT
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 32
- Registration Number
- NCT06891443
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇺🇸University of Minnesota Medical School, Minneapolis, Minnesota, United States
🇺🇸University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics, Philadelphia, Pennsylvania, United States
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
- Conditions
- Retinitis Pigmentosa (RP)Usher Syndrome Type 2Deaf BlindRetinal DiseaseEye Diseases, HereditaryEye Disorders CongenitalVision Disorders
- Interventions
- Other: No intervention, will not receive any active study intervention
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 81
- Registration Number
- NCT06627179
- Locations
- 🇺🇸
The University of California, San Francisco, San Francisco, California, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦McGill University Health Centre for Innovative Medicine, Montreal, Quebec, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Emerging Therapies Offer Hope for Usher Syndrome Patients
The Usher Syndrome market is poised for growth with emerging therapies addressing the root cause of the disease, offering alternatives to supportive care.